Table 1.
Summary of BTK inhibitors that have been evaluated in cancer studies.
| BTK Inhibitor | Study Type | Cancer Type |
|---|---|---|
| ibrutinib | in vitro | B cell lymphoma |
| chronic lymphocytic leukemia | ||
| pancreatic cancer | ||
| in vivo | chronic lymphocytic leukemia | |
| pancreatic cancer | ||
| colorectal cancer | ||
| breast cancer | ||
| acalabrutinib | in vitro | chronic lymphocytic leukemia |
| in vivo | B cell lymphoma | |
| chronic lymphocytic leukemia | ||
| pancreatic cancer * | ||
| urothelial cancer * | ||
| tirabrutinib | in vivo | pancreatic cancer |
| zanubrutinib | in vivo | mantle cell lymphoma * |
* indicated that the inhibitor is evaluated in the human clinical trials as the in vivo study; P.S. The BTK inhibitors including irbutinib and acalabrutinib are approved by FDA as the frontline treatment only for CLL and possibly other B cell lymphoma.